key: cord-0925424-0z5u6cdc authors: Lindner, Andreas K.; Nikolai, Olga; Kausch, Franka; Wintel, Mia; Hommes, Franziska; Gertler, Maximilian; Krüger, Lisa J.; Gaeddert, Mary; Tobian, Frank; Lainati, Federica; Köppel, Lisa; Seybold, Joachim; Corman, Victor M.; Drosten, Christian; Hofmann, Jörg; Sacks, Jilian A.; Mockenhaupt, Frank P.; Denkinger, Claudia M. title: Head-to-head comparison of SARS-CoV-2 antigen-detecting rapid test with self-collected anterior nasal swab versus professional-collected nasopharyngeal swab date: 2020-12-10 journal: Eur Respir J DOI: 10.1183/13993003.03961-2020 sha: dcd9d302c76946e55507e9e194204a1ab09544ca doc_id: 925424 cord_uid: 0z5u6cdc A number of antigen-detecting rapid diagnostic tests (Ag-RDTs) for SARS-CoV-2 are now commercially available and can result in rapid decisions on patient care, isolation and contact tracing at the point-of-care [1]. Two Ag-RDTs using nasopharyngeal (NP) swab samples meet WHO targets and are now approved through the WHO Emergency Use Listing procedure [2–4]. A number of antigen-detecting rapid diagnostic tests (Ag-RDTs) for SARS-CoV-2 are now commercially available and can result in rapid decisions on patient care, isolation and contact tracing at the point-ofcare [1] . Two Ag-RDTs using nasopharyngeal (NP) swab samples meet WHO targets and are now approved through the WHO Emergency Use Listing procedure [2] [3] [4] . NP swab samples are frequently perceived as uncomfortable by patients and must be collected by trained healthcare personnel with protective equipment. A more complex sampling technique could also result in an incorrect performance in the clinical reality with a possible consequence on test sensitivity. Evidence supports the use of alternative sampling methods for RT-PCR, including anterior nasal (AN) swabs collected by patients and some tests have received regulatory approval with AN samples [5, 6] . Considering the ease-of-use of Ag-RDTs, a reliable simple sampling method would not only allow selfsampling, but may also pave the way for self-testing. The primary objective of this prospective diagnostic accuracy study was a head-to-head comparison (positive and negative percent agreement) of a supervised, self-collected AN swab sample with a health care worker (professional)-collected NP swab sample, using a WHO-listed SARS-CoV-2 Ag-RDT against the reference standard RT-PCR collected from a NP/oropharyngeal (OP) swab. The secondary objective was to assess sensitivity and specificity for different sampling techniques with Ag-RDT. The study was continued until at least 30 positive NP swab samples according to Ag-RDT were obtained, as it was requested by the WHO to approve a novel sample type. This manufacturer-independent study was conducted in partnership with the Foundation of Innovative New Diagnostics (FIND), the WHO collaborating centre for COVID-19 diagnostics. The study protocol was approved by the ethical review committee at Heidelberg University Hospital for the study site in Berlin (registration number S-180/2020). The study took place at the ambulatory SARS-CoV-2 testing facility of Charité University Hospital (Charité-Universitätsmedizin Berlin, Germany) from 23 September to 14 October 2020. The study enrolled adults at high risk for SARS-CoV-2 infection according to clinical suspicion. Participants were excluded if either of the swabs for the Ag-RDT or the RT-PCR reference standard could not be collected. Participants underwent first an instructed, self-collected bilateral AN swab for the Ag-RDT. Verbal instruction was given to insert the swab horizontally 2-3 cm into the nostril and rotate it for 15 seconds against the nasal walls on each side. Deviations from the instructed technique were recorded. Subsequently, a combined OP/NP swab (eSwab from Copan with 1 ml Amies medium) as per institutional recommendations for RT-PCR, and a separate NP swab for the Ag-RDT were taken from different sides of the nose. The samples for the Ag-RDTs were collected using the swab provided by the manufacturer within the test kit. The Ag-RDT evaluated in this study was the STANDARD Q COVID-19 Ag Test (SD Biosensor, Inc. Gyeonggi-do, Korea; henceforth called STANDARD Q) [7] , which is also being distributed by Roche [8] . The test uses the lateral flow assay principle in a cassette-based format with a visual read-out after 15- (Table 1) . For most patients, the application of the flexible swab (meant for NP swab collection) in the anterior nose appeared unpleasant due to a tickling sensation and led to frequent sneezing. The strengths of the study are the rigorous methods, including standardized sampling, two independent blinded readers and an additional semi-quantitative assessment of Ag-RDT results. The cohort was representative, judging from the comparable sensitivity observed in the recent independent validation study of STANDARD Q (sensitivity 76.6%; CI 62.8-86.4) [4] . The study is limited as it was performed in a single centre. Also, the NP swab was usually rotated against the nasopharyngeal wall for less time than recommended by the manufacturer, which may have a negative impact on the sensitivity of the Ag-RDT with NP sampling, but also reflects the difficulty of collection of this sample type. In conclusion, this study demonstrates that supervised self-sampling from the anterior nose is a reliable alternative to professional nasopharyngeal sampling with STANDARD Q. The data will contribute to WHO recommendations for use of this test. Considering the ease-of-use of Ag-RDTs, self-sampling and potentially patient self-testing at home may be a future use case. If such testing could be repeated frequently and immediately ahead of situations when transmissions are likely to occur, self-testing with Ag-RDTs may have a significant impact on the pandemic. Further implementation studies on optimized self-sampling techniques and swabs (e.g. less flexible sponge swab) and the correct performance/interpretation of the test by patients themselves, are urgently needed to drive self-testing to scale. SARS-COV-2 Diagnostics Pipeline Antigen-detection in the diagnosis of SARS-CoV-2 infection using rapid immunoassays Global partnership to make available 120 million affordable, quality COVID-19 rapid tests for low-and middle-income countries Evaluation of the accuracy, ease of use and limit of detection of novel, rapid, antigen-detecting point-of-care diagnostics for SARS-CoV-2 Swabs Collected by Patients or Health Care Workers for SARS-CoV-2 Testing Interim Guidelines for Collecting H, and Testing Clinical Specimens for COVID-19 COVID-19 Ag STANDARDTM Q COVID-19 Ag Test 2020 Roche to launch SARS-CoV-2 Rapid Antigen Test in countries accepting CE mark, allowing fast triage decisions at point of care International external quality assessment for SARS-CoV-2 molecular detection and survey on clinical laboratory preparedness during the COVID-19 pandemic Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR The study was supported by FIND, Heidelberg University Hospital and Charité University Hospital internal funds, as well as a grant of the Ministry of Science, Research and the Arts of Baden-Württemberg, Germany. FIND provided input on the study design, and data analysis in collaboration with the rest of the study team. Author contributions: AKL, LJK, FL and CMD designed the study and developed standard operating procedures. AKL and ON implemented the study design, enrolled patients, performed laboratory work and led the writing of the manuscript. FPM and JS coordinated and supervised the study site. FK, MW, FH enrolled patients. MGe coordinated the testing facility. MGa, LK and FT led the data analysis. VC, JH and CD were responsible for PCR testing and contributed to the interpretation of the data. JAS supported the study design setup and the interpretation of the data. CMD was the principle investigator of the study. All authors have reviewed the manuscript.Data availability: All raw data and analysis code are available upon a request to the corresponding author.